{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:43:11Z","timestamp":1784698991260,"version":"3.55.0"},"publisher-location":"Berlin, Heidelberg","reference-count":152,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642247156","type":"print"},{"value":"9783642247163","type":"electronic"}],"license":[{"start":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T00:00:00Z","timestamp":1323475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T00:00:00Z","timestamp":1323475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-3-642-24716-3_20","type":"book-chapter","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T12:20:09Z","timestamp":1326716409000},"page":"433-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Weight-Reducing Side Effects of the Antiepileptic Agents Topiramate and Zonisamide"],"prefix":"10.1007","author":[{"given":"J.","family":"Antel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hebebrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,10]]},"reference":[{"issue":"1","key":"20_CR1_20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0920-1211(03)00039-1","volume":"54","author":"M Angehagen","year":"2003","unstructured":"Angehagen M, Ben-Menachem E, R\u00f6nnb\u00e4ck L, Hansson E (2003a) Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res 54(1):63\u201371","journal-title":"Epilepsy Res"},{"issue":"2","key":"20_CR2_20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1023\/A:1022393604014","volume":"28","author":"M Angehagen","year":"2003","unstructured":"Angehagen M, Ben-Menachem E, R\u00f6nnb\u00e4ck L, Hansson E (2003b) Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 28(2):333\u2013340","journal-title":"Neurochem Res"},{"issue":"2","key":"20_CR3_20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1046\/j.1471-4159.2003.02186.x","volume":"88","author":"M Angehagen","year":"2004","unstructured":"Angehagen M, Ben-Menachem E, Shank R, R\u00f6nnb\u00e4ck L, Hansson E (2004) Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem 88(2):320\u2013325","journal-title":"J Neurochem"},{"issue":"4","key":"20_CR4_20","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","volume":"94","author":"M Angehagen","year":"2005","unstructured":"Angehagen M, R\u00f6nnb\u00e4ck L, Hansson E, Ben-Menachem E (2005) Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem 94(4):1124\u20131130","journal-title":"J Neurochem"},{"key":"20_CR5_20","series-title":"CRC enzyme inhibitors series","volume-title":"Carbonic anhydrase: its inhibitors and activators","author":"J Antel","year":"2004","unstructured":"Antel J, Weber A, Sotriffer CA, Klebe G (2004) Multiple binding modes observed in X-ray structures of carbonic anhydrase-inhibitor complexes and other systems: consequences for structure-based drug design. In: Supuran CT, Scozzafava A, Conway J (eds) Carbonic anhydrase: its inhibitors and activators, CRC enzyme inhibitors series. CRC Press, Boca Raton"},{"issue":"14","key":"20_CR6_20","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1021\/jm058238r","volume":"49","author":"J Antel","year":"2006","unstructured":"Antel J, Gregory PC, Nordheim U (2006) CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J Med Chem 49(14):4008\u20134016","journal-title":"J Med Chem"},{"issue":"5","key":"20_CR7_20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.genhosppsych.2008.02.002","volume":"30","author":"B Arbaizar","year":"2008","unstructured":"Arbaizar B, G\u00f3mez-Acebo I, Llorca J (2008) Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 30(5):471\u2013475","journal-title":"Gen Hosp Psychiatry"},{"key":"20_CR8_20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0920-1211(02)00019-0","volume":"49","author":"AM Aribi","year":"2002","unstructured":"Aribi AM, Stringer JL (2002) Effects of antiepileptic drugs on extracellular pH regulation in the hippocampal CA1 region in vivo. Epilepsy Res 49:143\u2013151","journal-title":"Epilepsy Res"},{"issue":"Suppl","key":"20_CR9_20","doi-asserted-by":"publisher","first-page":"167S","DOI":"10.1038\/oby.2004.284","volume":"12","author":"A Astrup","year":"2004","unstructured":"Astrup A, Toubro S (2004) Topiramate: a new potential pharmacological treatment for obesity. Obes Res 12(Suppl):167S\u2013173S","journal-title":"Obes Res"},{"key":"20_CR10_20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1526-4637.2005.05035.x","volume":"6","author":"A Atli","year":"2005","unstructured":"Atli A, Dogra S (2005) Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med 6:225\u2013234","journal-title":"Pain Med"},{"issue":"6","key":"20_CR11_20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","volume":"22","author":"T Baptista","year":"2008","unstructured":"Baptista T, ElFakih Y, Uzc\u00e1tegui E, Sandia I, T\u00e1lamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22(6):477\u2013495","journal-title":"CNS Drugs"},{"issue":"12","key":"20_CR12_20","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1586\/erc.10.125","volume":"8","author":"H Bays","year":"2010","unstructured":"Bays H (2010) Phentermine, topiramate and their combination for the treatment of adiposopathy (\u2018sick fat\u2019) and metabolic disease. Expert Rev Cardiovasc Ther 8(12):1777\u20131801","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"Suppl 9","key":"20_CR13_20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1528-1167.2007.01402.x","volume":"48","author":"E Ben-Menachem","year":"2007","unstructured":"Ben-Menachem E (2007) Weight issues for people with epilepsy\u2013a review. Epilepsia 48(Suppl 9):42\u201345","journal-title":"Epilepsia"},{"issue":"4","key":"20_CR14_20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/oby.2003.78","volume":"11","author":"E Ben-Menachem","year":"2003","unstructured":"Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U (2003) Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11(4):556\u2013562","journal-title":"Obes Res"},{"key":"20_CR15_20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1471-2458-8-200","volume":"8","author":"A Bergh\u00f6fer","year":"2008","unstructured":"Bergh\u00f6fer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN (2008) Obesity prevalence from a European perspective: a systematic review. BMC Public Health 8:200","journal-title":"BMC Public Health"},{"key":"20_CR16_20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1085-9489.2004.009205.x","volume":"9","author":"S Bischofs","year":"2004","unstructured":"Bischofs S, Zelenka M, Sommer C (2004) Evaluation of topiramate as an anti-hyperalgesic and neuroprotective agent in the peripheral nervous system. J Peripher Nerv Syst 9:70\u201378","journal-title":"J Peripher Nerv Syst"},{"key":"20_CR17_20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1586\/14737175.4.6.935","volume":"4","author":"V Biton","year":"2004","unstructured":"Biton V (2004) Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 4:935\u2013943","journal-title":"Expert Rev Neurother"},{"key":"20_CR18_20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","volume":"30","author":"V Biton","year":"2007","unstructured":"Biton V (2007) Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30:230\u2013240","journal-title":"Clin Neuropharmacol"},{"key":"20_CR19_20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/oby.2003.102","volume":"11","author":"GA Bray","year":"2003","unstructured":"Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11:722\u2013733","journal-title":"Obes Res"},{"issue":"Suppl 2","key":"20_CR20_20","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1007\/s10072-006-0593-z","volume":"27","author":"G Bussone","year":"2006","unstructured":"Bussone G, Usai S, D'Amico D (2006) Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study. Neurol Sci 27(Suppl 2):S159\u2013S163","journal-title":"Neurol Sci"},{"key":"20_CR21_20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/088307380502000302","volume":"20","author":"J Campistol","year":"2005","unstructured":"Campistol J, Campos J, Casas C, Herranz JL (2005) Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 20:251\u2013253","journal-title":"J Child Neurol"},{"key":"20_CR22_20","first-page":"79","volume":"155","author":"A Capuano","year":"2004","unstructured":"Capuano A, Vollono C, Mei D, Pierguidi L, Ferraro D, Di Trapani G (2004) Antiepileptic drugs in migraine prophylaxis: state of the art. Clin Ter 155:79\u201387","journal-title":"Clin Ter"},{"key":"20_CR23_20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0960-894X(03)00029-5","volume":"13","author":"A Casini","year":"2003","unstructured":"Casini A, Antel J, Abbate F, Scozzafava A, David S, Waldeck H, Schafer S, Supuran CT (2003) Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates\/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 13:841\u2013845","journal-title":"Bioorg Med Chem Lett"},{"key":"20_CR24_20","first-page":"441","volume":"79","author":"WA Catterall","year":"1999","unstructured":"Catterall WA (1999) Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv Neurol 79:441\u2013456","journal-title":"Adv Neurol"},{"key":"20_CR25_20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1034\/j.1399-5618.2001.30501.x","volume":"3","author":"KN Chengappa","year":"2001","unstructured":"Chengappa KN, Gershon S, Levine J (2001) The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 3:215\u2013232","journal-title":"Bipolar Disord"},{"key":"20_CR26_20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00002508-200301000-00008","volume":"19","author":"MS Chong","year":"2003","unstructured":"Chong MS, Libretto SE (2003) The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 19:59\u201368","journal-title":"Clin J Pain"},{"key":"20_CR27_20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.expneurol.2009.11.002","volume":"221","author":"C Costa","year":"2010","unstructured":"Costa C, Tozzi A, Luchetti E, Siliquini S, Belcastro V, Tantucci M, Picconi B, Ientile R, Calabresi P, Pisani F (2010) Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 221:217\u2013224","journal-title":"Exp Neurol"},{"key":"20_CR28_20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.281.3.235","volume":"281","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB (1999) Weight control and risk factor reduction in obese subjects treated for 2\u00a0years with orlistat: a randomized controlled trial. JAMA 281:235\u2013242","journal-title":"JAMA"},{"key":"20_CR29_20","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.bmcl.2005.03.032","volume":"15","author":"G De Simone","year":"2005","unstructured":"De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT (2005) Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 15:2315\u20132320","journal-title":"Bioorg Med Chem Lett"},{"key":"20_CR30_20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.neuchi.2008.10.004","volume":"54","author":"P Dhellemmes","year":"2008","unstructured":"Dhellemmes P, Defoort S, Vinchon M (2008) Benign intracranial hypertension: the role of medical treatment. Neurochirurgie 54:717\u2013720","journal-title":"Neurochirurgie"},{"key":"20_CR31_20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd1495","volume":"3","author":"V Di Marzo","year":"2004","unstructured":"Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771\u2013784","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"20_CR32_20","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1111\/j.1528-1157.2000.tb06047.x","volume":"41","author":"SJ Dodgson","year":"2000","unstructured":"Dodgson SJ, Shank RP, Maryanoff BE (2000) Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41(Suppl 1):S35\u2013S39","journal-title":"Epilepsia"},{"key":"20_CR33_20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/01.wnf.0000150866.98887.77","volume":"27","author":"ME Drake Jr","year":"2004","unstructured":"Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD (2004) Open-label zonisamide for refractory migraine. Clin Neuropharmacol 27:278\u2013280","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"20_CR34_20","first-page":"198","volume":"45","author":"SM Dursun","year":"2000","unstructured":"Dursun SM, Devarajan S (2000) Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45(2):198","journal-title":"Can J Psychiatry"},{"key":"20_CR35_20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.52.7.1338","volume":"52","author":"RD Elterman","year":"1999","unstructured":"Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G (1999) A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 52:1338\u20131344","journal-title":"Neurology"},{"key":"20_CR36_20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1006\/ebeh.2002.0339","volume":"3","author":"T Fakhoury","year":"2002","unstructured":"Fakhoury T, Murray L, Seger D, McLean M, Abou-Khalil B (2002) Topiramate overdose: clinical and laboratory features. Epilepsy Behav 3:185\u2013189","journal-title":"Epilepsy Behav"},{"issue":"3","key":"20_CR37_20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.2009.2014","volume":"303","author":"KM Flegal","year":"2010","unstructured":"Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among us adults, 1999\u20132008. JAMA 303(3):235\u2013241","journal-title":"JAMA"},{"key":"20_CR38_20","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/oby.2010.6","volume":"18","author":"RJ Fountaine","year":"2010","unstructured":"Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA (2010) Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 18:1646\u20131651","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"20_CR39_20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-895X(25)09256-9","volume":"42","author":"J Francis","year":"1992","unstructured":"Francis J, Burnham WM (1992) [3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels. Mol Pharmacol 42(6):1097\u20131103","journal-title":"Mol Pharmacol"},{"issue":"7","key":"20_CR40_20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s12098-007-0124-9","volume":"74","author":"EL Fung","year":"2007","unstructured":"Fung EL, Nelson EA (2007) Oligohydrosis underestimated side effect with topiramate treatment. Indian J Pediatr 74(7):694","journal-title":"Indian J Pediatr"},{"key":"20_CR41_20","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","volume":"289","author":"KM Gadde","year":"2003","unstructured":"Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR (2003) Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289:1820\u20131825","journal-title":"JAMA"},{"key":"20_CR154_20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4088\/JCP.v68n0809","volume":"68","author":"KM Gadde","year":"2007","unstructured":"Gadde KM, Yonish GM, Foust MS, Wagner HR (2007) Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 68:1226\u20139","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"20_CR42_20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1590\/S0004-282X2010000200024","volume":"68","author":"CN Gaspari","year":"2010","unstructured":"Gaspari CN, Guerreiro CA (2010) Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr 68(2):277\u2013281","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"20_CR43_20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2710.2009.01084.x","volume":"35","author":"S Gebhardt","year":"2010","unstructured":"Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, K\u00fchnau W, Schmidtke J, Remschmidt H, Hebebrand J (2010) Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 35(2):207\u2013211","journal-title":"J Clin Pharm Ther"},{"key":"20_CR44_20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00213-005-2189-3","volume":"180","author":"S Ghelardoni","year":"2005","unstructured":"Ghelardoni S, Bazinet RP, Rapoport SI, Bosetti F (2005) Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berl) 180:523\u2013529","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl 1","key":"20_CR45_20","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","volume":"41","author":"JW Gibbs III","year":"2000","unstructured":"Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl 1):S10\u2013S16","journal-title":"Epilepsia"},{"issue":"18","key":"20_CR46_20","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1523\/JNEUROSCI.23-18-07069.2003","volume":"23","author":"DS Gryder","year":"2003","unstructured":"Gryder DS, Rogawski MA (2003) Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23(18):7069\u20137074","journal-title":"J Neurosci"},{"issue":"6","key":"20_CR47_20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JCP.0b013e3181fab67d","volume":"30","author":"MK Hahn","year":"2010","unstructured":"Hahn MK, Remington G, Bois D, Cohn T (2010) Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30(6):706\u2013710","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR48_20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1185\/030079904125003313","volume":"20","author":"H Hasegawa","year":"2004","unstructured":"Hasegawa H (2004) Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin 20:577\u2013580","journal-title":"Curr Med Res Opin"},{"key":"20_CR49_20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000321537","volume":"3","author":"J Hebebrand","year":"2010","unstructured":"Hebebrand J, Volckmar AL, Knoll N, Hinney A (2010) Chipping away the \u2018missing heritability\u2019: GIANT steps forward in the molecular elucidation of obesity \u2013 but still lots to go. Obes Facts 3:294\u2013303","journal-title":"Obes Facts"},{"key":"20_CR50_20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0028-3908(01)00171-X","volume":"42","author":"AI Herrero","year":"2002","unstructured":"Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM (2002) Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 42:210\u2013220","journal-title":"Neuropharmacology"},{"key":"20_CR51_20","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1213\/01.ANE.0000062652.66661.97","volume":"96","author":"AH Hord","year":"2003","unstructured":"Hord AH, Denson DD, Chalfoun AG, Azevedo MI (2003) The effect of systemic zonisamide (Zonegran) on thermal hyperalgesia and mechanical allodynia in rats with an experimental mononeuropathy. Anesth Analg 96:1700\u20131706; table of contents","journal-title":"Anesth Analg"},{"issue":"2","key":"20_CR52_20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.npp.1301209","volume":"32","author":"KL Houseknecht","year":"2007","unstructured":"Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007) Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32(2):289\u2013297","journal-title":"Neuropsychopharmacology"},{"key":"20_CR53_20","unstructured":"TOP Institute Pharma; Project T2-105 (2006\u20132011) Investigation of drug-induced weight alterations to identify novel therapeutic strategies for the treatment of obesity, dyslipidemia and diabetes. Principal investigator: Elwin Verheij; partners: Abbott (formerly Solvay Pharmaceuticals), Danone Research (formerly Numico), Leiden University Medical Center, Netherlands Institute for Neurosciences, PRA International, TNO, University Medical Center Groningen http:\/\/www.tipharma.com\/projects\/cardiovascular-diseases\/drug-induced-weight-alteration.html"},{"key":"20_CR151_20","unstructured":"Jackson HC, Cheetham SC, Gregory PC, Antel J (2007). Effect of chronic administration of topiramate and phentermine, alone and in combination, in an animal model of dietary-induced obesity. Neuroscience Program No 629.15, Society for Neuroscience: San Diego, CA"},{"key":"20_CR54_20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1517\/14656566.1.6.1245","volume":"1","author":"KK Jain","year":"2000","unstructured":"Jain KK (2000) An assessment of zonisamide as an anti-epileptic drug. Expert Opin Pharmacother 1:1245\u20131260","journal-title":"Expert Opin Pharmacother"},{"issue":"9248","key":"20_CR55_20","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"WP James","year":"2000","unstructured":"James WP, Astrup A, Finer N, Hilsted J, Kopelman P, R\u00f6ssner S, Saris WH, Van Gaal LF (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 356(9248):2119\u20132125","journal-title":"Lancet"},{"issue":"10","key":"20_CR56_20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, Investigators SCOUT (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363(10):905\u2013917","journal-title":"N Engl J Med"},{"issue":"1","key":"20_CR57_20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","volume":"22","author":"C Johannessen Landmark","year":"2008","unstructured":"Johannessen Landmark C (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1):27\u201347","journal-title":"CNS Drugs"},{"issue":"3","key":"20_CR58_20","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1017\/S0317167100034855","volume":"25","author":"MW Jones","year":"1998","unstructured":"Jones MW (1998) Topiramate \u2013 safety and tolerability. Can J Neurol Sci 25(3):S13\u2013S15","journal-title":"Can J Neurol Sci"},{"issue":"12","key":"20_CR59_20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/nrd2775","volume":"7","author":"D Jones","year":"2008","unstructured":"Jones D (2008) End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7(12):961\u2013962","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"20_CR60_20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000026529","volume":"38","author":"KM Kelly","year":"1998","unstructured":"Kelly KM (1998) Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology 38(3):139\u2013144","journal-title":"Neuropsychobiology"},{"issue":"1","key":"20_CR61_20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pbb.2010.07.020","volume":"97","author":"GA Kennett","year":"2010","unstructured":"Kennett GA, Clifton PG (2010) New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 97(1):63\u201383","journal-title":"Pharmacol Biochem Behav"},{"key":"20_CR62_20","first-page":"600","volume":"52","author":"CS Kim","year":"2003","unstructured":"Kim CS (2003) Zonisamide effective for weight loss in women. J Fam Pract 52:600\u2013601","journal-title":"J Fam Pract"},{"issue":"1","key":"20_CR63_20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.schres.2005.10.001","volume":"82","author":"JH Kim","year":"2006","unstructured":"Kim JH, Yim SJ, Nam JH (2006) A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82(1):115\u2013117","journal-title":"Schizophr Res"},{"issue":"8","key":"20_CR64_20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/oby.2005.161","volume":"13","author":"KM Klein","year":"2005","unstructured":"Klein KM, Hamer HM, Reis J, Schmidtke J, Oertel WH, Theisen FM, Hebebrand J, Rosenow F (2005) Weight change in monozygotic twins treated with valproate. Obes Res 13(8):1330\u20131334","journal-title":"Obes Res"},{"issue":"3","key":"20_CR65_20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S0887-8994(02)00511-8","volume":"28","author":"JF Knudsen","year":"2003","unstructured":"Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA (2003) Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol 28(3):184\u2013189","journal-title":"Pediatr Neurol"},{"key":"20_CR66_20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/089277902753752188","volume":"16","author":"RL Kuo","year":"2002","unstructured":"Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE (2002) Topiramate-induced nephrolithiasis. J Endourol 16:229\u2013231","journal-title":"J Endourol"},{"key":"20_CR67_20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1399-5618.2006.00276.x","volume":"8","author":"SF Kushner","year":"2006","unstructured":"Kushner SF, Khan A, Lane R, Olson WH (2006) Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 8:15\u201327","journal-title":"Bipolar Disord"},{"issue":"4","key":"20_CR68_20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.0013-9580.2005.35304.x","volume":"46","author":"JB Kuzmiski","year":"2005","unstructured":"Kuzmiski JB, Barr W, Zamponi GW, MacVicar BA (2005) Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. Epilepsia 46(4):481\u2013489","journal-title":"Epilepsia"},{"key":"20_CR69_20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.58.3.368","volume":"58","author":"R Kuzniecky","year":"2002","unstructured":"Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, Hetherington H (2002) Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58:368\u2013372","journal-title":"Neurology"},{"key":"20_CR150_20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1046\/j.1528-1157.2002.32601.x","volume":"43","author":"T Leniger","year":"2002","unstructured":"Leniger T, Wiemann M, Bingmann D, Widman G, Hufnagel A, Bonnet U (2002) Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia 43:469\u201374","journal-title":"Epilepsia"},{"issue":"5","key":"20_CR70_20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/sj.bjp.0705850","volume":"142","author":"T Leniger","year":"2004","unstructured":"Leniger T, Th\u00f6ne J, Wiemann M (2004) Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl-\/HCO3-exchange. Br J Pharmacol 142(5):831\u2013842","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"20_CR71_20","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.seizure.2004.04.016","volume":"13","author":"IE Leppik","year":"2004","unstructured":"Leppik IE (2004) Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13(Suppl 1):S5\u2013S9; discussion S10","journal-title":"Seizure"},{"key":"20_CR72_20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.4088\/JCP.v63n1116a","volume":"63","author":"E Levy","year":"2002","unstructured":"Levy E, Margolese HC, Chouinard G (2002) Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 63:1045","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"20_CR73_20","first-page":"e234","volume":"14","author":"E L\u00e9vy","year":"2007","unstructured":"L\u00e9vy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC (2007) Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 14(2):e234\u2013e239","journal-title":"Can J Clin Pharmacol"},{"key":"20_CR74_20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","volume":"142","author":"Z Li","year":"2005","unstructured":"Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532\u2013546","journal-title":"Ann Intern Med"},{"key":"20_CR75_20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.metabol.2006.06.013","volume":"55","author":"Y Liang","year":"2006","unstructured":"Liang Y, She P, Wang X, Demarest K (2006) The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 55:1411\u20131419","journal-title":"Metabolism"},{"key":"20_CR76_20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/sj.ijo.0801969","volume":"26","author":"Y Linne","year":"2002","unstructured":"Linne Y, Hemmingsson E, Adolfsson B, Ramsten J, R\u00f6ssner S (2002) Patient expectations of obesity treatment\u2014the experience from a day-care unit. Int J Obes 26:739\u2013741","journal-title":"Int J Obes"},{"key":"20_CR77_20","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/npp.2010.21","volume":"35","author":"L Maayan","year":"2010","unstructured":"Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35:1520\u20131530","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"20_CR78_20","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.2337\/db10-0449","volume":"59","author":"PJF Martins","year":"2010","unstructured":"Martins PJF, Haas M, Obici S (2010) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59(10):2418\u20132425","journal-title":"Diabetes"},{"key":"20_CR79_20","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1021\/jm900141j","volume":"52","author":"BE Maryanoff","year":"2009","unstructured":"Maryanoff BE (2009) 2009 Edward E Smissman Award. Pharmaceutical \u201cgold\u201d from neurostabilizing agents: topiramate and successor molecules. J Med Chem 52:3431\u20133440","journal-title":"J Med Chem"},{"key":"20_CR80_20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1021\/jm00388a023","volume":"30","author":"BE Maryanoff","year":"1987","unstructured":"Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP (1987) Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-d-fructopyranose sulfamate and related compounds. J Med Chem 30:880\u2013887","journal-title":"J Med Chem"},{"key":"20_CR81_20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1021\/jm970790w","volume":"41","author":"BE Maryanoff","year":"1998","unstructured":"Maryanoff BE, Costanzo MJ, Nortey SO, Greco MN, Shank RP, Schupsky JJ, Ortegon MP, Vaught JL (1998) Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J Med Chem 41:1315\u20131343","journal-title":"J Med Chem"},{"key":"20_CR82_20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/jm0109199","volume":"45","author":"B Masereel","year":"2002","unstructured":"Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT (2002) Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem 45:312\u2013320","journal-title":"J Med Chem"},{"issue":"10","key":"20_CR83_20","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/10408390903372599","volume":"49","author":"EJ McAllister","year":"2009","unstructured":"McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, Benca RM, Biggio J, Boggiano MM, Eisenmann JC, Elobeid M, Fontaine KR, Gluckman P, Hanlon EC, Katzmarzyk P, Pietrobelli A, Redden DT, Ruden DM, Wang C, Waterland RA, Wright SM, Allison DB (2009) Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 49(10):868\u2013913","journal-title":"Crit Rev Food Sci Nutr"},{"key":"20_CR84_20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4088\/JCP.v65n0108","volume":"65","author":"SL McElroy","year":"2004","unstructured":"McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE (2004) Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 65:50\u201356","journal-title":"J Clin Psychiatry"},{"key":"20_CR85_20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/070674370505000705","volume":"50","author":"RS McIntyre","year":"2005","unstructured":"McIntyre RS, Riccardelli R, Binder C, Kusumakar V (2005) Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 50:415\u2013422","journal-title":"Can J Psychiatry"},{"issue":"Suppl 1","key":"20_CR86_20","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1111\/j.1528-1157.2000.tb02166.x","volume":"41","author":"MJ McLean","year":"2000","unstructured":"McLean MJ, Bukhari AA, Wamil AW (2000) Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 41(Suppl 1):S21\u2013S24","journal-title":"Epilepsia"},{"issue":"2","key":"20_CR87_20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1254\/jphs.FP0040032","volume":"95","author":"NC McNaughton","year":"2004","unstructured":"McNaughton NC, Davies CH, Randall A (2004) Inhibition of alpha(1E) Ca(2+) channels by carbonic anhydrase inhibitors. J Pharmacol Sci 95(2):240\u2013247","journal-title":"J Pharmacol Sci"},{"issue":"1\u20134","key":"20_CR88_20","first-page":"13","volume":"39","author":"T Mimaki","year":"1990","unstructured":"Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (1990a) Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ 39(1\u20134):13\u201317","journal-title":"Med J Osaka Univ"},{"issue":"1\u20134","key":"20_CR89_20","first-page":"19","volume":"39","author":"T Mimaki","year":"1990","unstructured":"Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (1990b) [3H]Zonisamide binding in rat brain. Med J Osaka Univ 39(1\u20134):19\u201322","journal-title":"Med J Osaka Univ"},{"key":"20_CR152_20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1755-5949.2010.00172.x","volume":"17","author":"PJ Nathan","year":"2011","unstructured":"Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET (2011) Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs. CNS Neurosci Ther. 17:490\u2013505","journal-title":"CNS Neurosci Ther."},{"key":"20_CR90_20","unstructured":"NCT00203450 (2003) Zonegran for the treatment of weight gain associated with psychotropic medication use: a placebo-controlled trial; Sponsor: Tuscaloosa Research & Education Advancement Corporation; Study Start Date: May 2003"},{"key":"20_CR91_20","unstructured":"NCT00363376 (2008) A double-blind, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain; Sponsor: Lindner Center of HOPE; Study Start Date: January 2008"},{"key":"20_CR92_20","unstructured":"NCT00401973 (2006) The assessment of the safety, efficacy, and practicality of an algorithm including amantadine, metformin and zonisamide for the prevention of olanzapine-associated weight gain in outpatients with schizophrenia; Sponsor: Eli Lilly and Company; Study Start Date: November 2006"},{"key":"20_CR93_20","unstructured":"NCT00734435 (2008) A proof of concept, multi-center, randomized, double-blind, parallel, placebo-controlled, study of zonisamide sustained release (SR) 360\u00a0mg versus placebo in the prevention of weight gain associated with olanzapine therapy for psychosis; Sponsor: Orexigen Therapeutics, Inc.; Study Start Date: September 2008"},{"key":"20_CR94_20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.jcp.0000162806.46453.38","volume":"25","author":"MK Nickel","year":"2005","unstructured":"Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P (2005) Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 25:211\u2013217","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 2","key":"20_CR95_20","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.eplepsyres.2005.11.007","volume":"68","author":"S Ohtahara","year":"2006","unstructured":"Ohtahara S (2006) Zonisamide in the management of epilepsy \u2013 Japanese experience. Epilepsy Res 68(Suppl 2):S25\u2013S33","journal-title":"Epilepsy Res"},{"key":"20_CR96_20","first-page":"192","volume":"22","author":"KJ Oommen","year":"1999","unstructured":"Oommen KJ, Mathews S (1999) Zonisamide, a new anti-epileptic drug. Clin Neuropharmacol 22:192\u2013200","journal-title":"Clin Neuropharmacol"},{"key":"20_CR97_20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1006\/phrs.1997.0124","volume":"35","author":"E Perucca","year":"1997","unstructured":"Perucca E (1997) A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 35:241\u2013256","journal-title":"Pharmacol Res"},{"key":"20_CR98_20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/oby.2000.84","volume":"8","author":"F Picard","year":"2000","unstructured":"Picard F, Deshaies Y, Lalonde J, Samson P, Richard D (2000) Topiramate reduces energy and fat gains in lean (Fa\/?) and obese (fa\/fa) Zucker rats. Obes Res 8:656\u2013663","journal-title":"Obes Res"},{"issue":"1","key":"20_CR99_20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00023210-200721010-00005","volume":"21","author":"RM Post","year":"2007","unstructured":"Post RM, Ketter TA, Uhde T, Ballenger JC (2007) Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 21(1):47\u201371","journal-title":"CNS Drugs"},{"key":"20_CR100_20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/01.WNL.0000137341.89781.14","volume":"63","author":"P Raskin","year":"2004","unstructured":"Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, Vinik AI (2004) Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63:865\u2013873","journal-title":"Neurology"},{"key":"20_CR101_20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1046\/j.1528-1157.2002.09902.x","volume":"43","author":"J Reis","year":"2002","unstructured":"Reis J, Tergau F, Hamer HM, Muller HH, Knake S, Fritsch B, Oertel WH, Rosenow F (2002) Topiramate selectively decreases intracortical excitability in human motor cortex. Epilepsia 43:1149\u20131156","journal-title":"Epilepsia"},{"key":"20_CR102_20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.33588\/rn.3402.2001335","volume":"34","author":"R Ribacoba Montero","year":"2002","unstructured":"Ribacoba Montero R, Salas Puig X (2002) Efficacy and tolerability of long term topiramate in drug resistant epilepsy in adults. Rev Neurol 34:101\u2013105","journal-title":"Rev Neurol"},{"key":"20_CR103_20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S0899-9007(00)00452-4","volume":"16","author":"D Richard","year":"2000","unstructured":"Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y (2000) Influence of topiramate in the regulation of energy balance. Nutrition 16:961\u2013966","journal-title":"Nutrition"},{"key":"20_CR104_20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.ijo.0801873","volume":"26","author":"D Richard","year":"2002","unstructured":"Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y (2002) The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 26:344\u2013353","journal-title":"Int J Obes Relat Metab Disord"},{"key":"20_CR105_20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1124\/jpet.104.067884","volume":"310","author":"M Rinaldi-Carmona","year":"2004","unstructured":"Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, P\u00e9rio A, Poncelet M, Maruani J, Arnone M, Finance O, Soubri\u00e9 P, Le Fur G (2004) SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 310:905\u2013914","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"20_CR106_20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.eplepsyres.2006.02.004","volume":"69","author":"MA Rogawski","year":"2006","unstructured":"Rogawski MA (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69(3):273\u2013294","journal-title":"Epilepsy Res"},{"issue":"7","key":"20_CR107_20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrn1430","volume":"5","author":"MA Rogawski","year":"2004","unstructured":"Rogawski MA, L\u00f6scher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5(7):553\u2013564","journal-title":"Nat Rev Neurosci"},{"key":"20_CR108_20","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/S0149-2918(97)80006-9","volume":"19","author":"WE Rosenfeld","year":"1997","unstructured":"Rosenfeld WE (1997) Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19:1294\u20131308","journal-title":"Clin Ther"},{"issue":"1","key":"20_CR109_20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1):32\u201341","journal-title":"Synapse"},{"issue":"6","key":"20_CR110_20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.neuropharm.2003.11.028","volume":"46","author":"E Russo","year":"2004","unstructured":"Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G (2004) Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 46(6):865\u2013878","journal-title":"Neuropharmacology"},{"issue":"5","key":"20_CR111_20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/11584800-000000000-00000","volume":"10","author":"AJ Scheen","year":"2010","unstructured":"Scheen AJ (2010) Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 10(5):321\u2013334","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1\u20132","key":"20_CR112_20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.brainres.2005.07.061","volume":"1058","author":"S Schubert","year":"2005","unstructured":"Schubert S, Brandl U, Brodhun M, Ulrich C, Spaltmann J, Fiedler N, Bauer R (2005) Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res 1058(1\u20132):129\u2013136","journal-title":"Brain Res"},{"issue":"Suppl 1","key":"20_CR113_20","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.seizure.2004.04.015","volume":"13","author":"M Seino","year":"2004","unstructured":"Seino M (2004) Review of zonisamide development in Japan. Seizure 13(Suppl 1):S2\u2013S4","journal-title":"Seizure"},{"key":"20_CR114_20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1528-1157.1994.tb02459.x","volume":"35","author":"RP Shank","year":"1994","unstructured":"Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE (1994) Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 35:450\u2013460","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"20_CR115_20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","volume":"41","author":"RP Shank","year":"2000","unstructured":"Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41(Suppl 1):S3\u2013S9","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"20_CR116_20","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1111\/j.1528-1157.2000.tb06046.x","volume":"41","author":"GJ Sills","year":"2000","unstructured":"Sills GJ, Leach JP, Kilpatrick WS, Fraser CM, Thompson GG, Brodie MJ (2000) Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt. Epilepsia 41(Suppl 1):S30\u2013S34","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"20_CR117_20","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1111\/j.1528-1157.2000.tb02171.x","volume":"41","author":"S Skradski","year":"2000","unstructured":"Skradski S, White HS (2000) Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 41(Suppl 1):S45\u2013S47","journal-title":"Epilepsia"},{"key":"20_CR118_20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0920-1211(00)00118-2","volume":"40","author":"JL Stringer","year":"2000","unstructured":"Stringer JL (2000) A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res 40:147\u2013153","journal-title":"Epilepsy Res"},{"key":"20_CR119_20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168\u2013181","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"20_CR120_20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1517\/14728214.13.2.383","volume":"13","author":"CT Supuran","year":"2008","unstructured":"Supuran CT, Di Fiore A, De Simone G (2008) Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 13(2):383\u2013392","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"20_CR121_20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/bbrc.1996.1133","volume":"225","author":"K Takaya","year":"1996","unstructured":"Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakao K (1996) Molecular cloning of rat leptin receptor isoform complementary DNAs \u2013 identification of a missense mutation in Zucker fatty (fa\/fa) rats. Biochem Biophys Res Commun 225(1):75\u201383","journal-title":"Biochem Biophys Res Commun"},{"key":"20_CR122_20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00210-005-0006-5","volume":"372","author":"M Tanabe","year":"2005","unstructured":"Tanabe M, Sakaue A, Takasu K, Honda M, Ono H (2005) Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse. Naunyn Schmiedebergs Arch Pharmacol 372:107\u2013114","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"20_CR123_20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(24)38047-4","volume":"288","author":"S Taverna","year":"1999","unstructured":"Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G (1999) Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 288:960\u2013968","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"20_CR124_20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.158.5.816","volume":"158","author":"FM Theisen","year":"2001","unstructured":"Theisen FM, Cichon S, Linden A, Martin M, Remschmidt H, Hebebrand J (2001) Clozapine and weight gain. Am J Psychiatry 158(5):816","journal-title":"Am J Psychiatry"},{"key":"20_CR125_20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.tpj.6500418","volume":"7","author":"FM Theisen","year":"2007","unstructured":"Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J (2007) No evidence for binding of clozapine, olanzapine and\/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J 7:275\u2013281","journal-title":"Pharmacogenomics J"},{"key":"20_CR126_20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.eplepsyres.2007.11.009","volume":"79","author":"J Thone","year":"2008","unstructured":"Thone J, Leniger T, Splettstosser F, Wiemann M (2008) Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res 79:105\u2013111","journal-title":"Epilepsy Res"},{"key":"20_CR127_20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.amjcard.2005.03.053","volume":"96","author":"S Tonstad","year":"2005","unstructured":"Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, Fitchet M (2005) Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 96:243\u2013251","journal-title":"Am J Cardiol"},{"issue":"1","key":"20_CR128_20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/sj.ijo.0803382","volume":"31","author":"H Toplak","year":"2007","unstructured":"Toplak H, Hamann H, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 31(1):138\u2013146","journal-title":"Int J Obes"},{"issue":"1\u20132","key":"20_CR129_20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-328X(03)00183-9","volume":"116","author":"Y Ueda","year":"2003","unstructured":"Ueda Y, Doi T, Tokumaru J, Willmore LJ (2003) Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 116(1\u20132):1\u20136","journal-title":"Brain Res Mol Brain Res"},{"issue":"Suppl 2","key":"20_CR130_20","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.2337\/dc08-s258","volume":"31","author":"L Van Gaal","year":"2008","unstructured":"Van Gaal L, Pi-Sunyer X, Despr\u00e9s JP, McCarthy C, Scheen A (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31(Suppl 2):S229\u2013S240","journal-title":"Diabetes Care"},{"key":"20_CR131_20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1586\/14737175.6.1.19","volume":"6","author":"L Van Passel","year":"2006","unstructured":"Van Passel L, Arif H, Hirsch LJ (2006) Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother 6:19\u201331","journal-title":"Expert Rev Neurother"},{"key":"20_CR132_20","doi-asserted-by":"crossref","unstructured":"Vasudev K, Macritchie K, Geddes J, Watson S, Young A (2006) Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev CD003384","DOI":"10.1002\/14651858.CD003384.pub2"},{"key":"20_CR133_20","unstructured":"VI-0521(QNEXA\u00ae) Briefing document (2010) http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm218821.pdf"},{"key":"20_CR134_20","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1210\/jc.2004-2376","volume":"90","author":"A Vinik","year":"2005","unstructured":"Vinik A (2005) Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 90:4936\u20134945","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"20_CR135_20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1358\/dot.2010.46.4.1445795","volume":"46","author":"D Vohora","year":"2010","unstructured":"Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK (2010) Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc) 46(4):265\u2013277","journal-title":"Drugs Today (Barc)"},{"key":"20_CR136_20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0272-0590(88)90158-3","volume":"11","author":"RM Walker","year":"1988","unstructured":"Walker RM, DiFonzo CJ, Barsoum NJ, Smith GS, Macallum GE (1988) Chronic toxicity of the anticonvulsant zonisamide in beagle dogs. Fundam Appl Toxicol 11:333\u2013342","journal-title":"Fundam Appl Toxicol"},{"issue":"12","key":"20_CR137_20","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1038\/npp.2008.9","volume":"33","author":"NM Wallingford","year":"2008","unstructured":"Wallingford NM, Sinnayah P, Bymaster FP, Gadde KM, Krishnan RK, McKinney AA, Landbloom RP, Tollefson GD, Cowley MA (2008) Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 33(12):2922\u20132933","journal-title":"Neuropsychopharmacology"},{"key":"20_CR153_20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jpsychires.2007.05.005","volume":"42","author":"PW Wang","year":"2008","unstructured":"Wang PW, Yang YS, Chandler RA, Nowakowska C, Alarcon AM, Culver J, Ketter TA (2008) Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res 42:451\u20137","journal-title":"J Psychiatr Res"},{"issue":"5","key":"20_CR138_20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/j.1528-1167.2006.00541.x","volume":"47","author":"M Weiergr\u00e4ber","year":"2006","unstructured":"Weiergr\u00e4ber M, Henry M, Krieger A, Kamp M, Radhakrishnan K, Hescheler J, Schneider T (2006) Altered seizure susceptibility in mice lacking the Ca(v)2.3 E-type Ca2+ channel. Epilepsia 47(5):839\u2013850","journal-title":"Epilepsia"},{"key":"20_CR139_20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1592\/phco.26.3.375","volume":"26","author":"RG Wenzel","year":"2006","unstructured":"Wenzel RG, Schwarz K, Padiyara RS (2006) Topiramate for migraine prevention. Pharmacotherapy 26:375\u2013387","journal-title":"Pharmacotherapy"},{"key":"20_CR140_20","first-page":"275","volume":"56","author":"A Wieczorkiewicz-Plaza","year":"2004","unstructured":"Wieczorkiewicz-Plaza A, Plaza P, Maciejewski R, Czuczwar M, Przesmycki K (2004) Effect of topiramate on mechanical allodynia in neuropathic pain model in rats. Pol J Pharmacol 56:275\u2013278","journal-title":"Pol J Pharmacol"},{"key":"20_CR141_20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","volume":"28","author":"J Wilding","year":"2004","unstructured":"Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28:1399\u20131410","journal-title":"Int J Obes Relat Metab Disord"},{"key":"20_CR142_20","doi-asserted-by":"publisher","first-page":"E617","DOI":"10.1152\/ajpendo.00437.2004","volume":"288","author":"JJ Wilkes","year":"2005","unstructured":"Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM (2005a) Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 288:E617\u2013E624","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"20_CR143_20","doi-asserted-by":"publisher","first-page":"E1015","DOI":"10.1152\/ajpendo.00169.2005","volume":"289","author":"JJ Wilkes","year":"2005","unstructured":"Wilkes JJ, Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM (2005b) Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 289:E1015\u2013E1022","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl 1","key":"20_CR144_20","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.seizure.2004.04.018","volume":"13","author":"K Yagi","year":"2004","unstructured":"Yagi K (2004) Overview of Japanese experience-controlled and uncontrolled trials. Seizure 13(Suppl 1):S11\u2013S15; discussion S16","journal-title":"Seizure"},{"issue":"2\u20133","key":"20_CR145_20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.eplepsyres.2009.01.015","volume":"84","author":"S Yamamura","year":"2009","unstructured":"Yamamura S, Hamaguchi T, Ohoyama K, Sugiura Y, Suzuki D, Kanehara S, Nakagawa M, Motomura E, Matsumoto T, Tanii H, Shiroyama T, Okada M (2009) Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res 84(2\u20133):172\u2013186","journal-title":"Epilepsy Res"},{"issue":"10","key":"20_CR146_20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0899-9007(00)00451-2","volume":"16","author":"DA York","year":"2000","unstructured":"York DA, Singer L, Thomas S, Bray GA (2000) Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 16(10):967\u2013975","journal-title":"Nutrition"},{"key":"20_CR147_20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4088\/JCP.v64n0215f","volume":"64","author":"DF Zullino","year":"2003","unstructured":"Zullino DF, Krenz S, Besson J (2003) AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD. J Clin Psychiatry 64:219\u2013220","journal-title":"J Clin Psychiatry"}],"container-title":["Handbook of Experimental Pharmacology","Appetite Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-24716-3_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T21:41:19Z","timestamp":1742334079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-24716-3_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"ISBN":["9783642247156","9783642247163"],"references-count":152,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-24716-3_20","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]},"assertion":[{"value":"10 December 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}